The End of Age-Related Disease? #longevity #science

This week in longevity: BioAge dosed its first Phase 2 patient for an oral anti-inflammatory drug found by studying slow-agers. NewLimit scaled up manufacturing on its liver reprogramming medicine and showed new results in blood vessel cells. Buck Institute revealed how the APOE2 "longevity gene" helps neurons repair DNA. And a massive Nature study in mice found the genes driving mortality risk change completely across life stages — suggesting timing matters as much as the target. Brought to you by ASLF Formulas. https://aslf-formulas.com/ Sources:BioAge BGE-102 Phase 2: https://www.globenewswire.com/news-release/2026/06/16/3312476/0/en/BioAge-Labs-Announces-First-Participant-Dosed-in-QUELL-CV-a-Phase-2-Proof-of-Concept-Trial-of-BGE-102-a-Novel-Oral-NLRP3-Inhibitor-in-Patients-at-Elevated-Cardiovascular-Risk.html NewLimit Progress Update: https://blog.newlimit.com/p/2026-may-june-progress-update Buck Institute APOE2 study: https://www.buckinstitute.org/news/longevity-linked-apoe2-gene-variant-helps-neurons-repair-dna-and-resist-aging/ Nature VITA loci study: https://www.nature.com/articles/s41586-026-10407-9 #Longevity #Biohacking #AntiAging